X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders (QoQ) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.22% |
| Mar 31, 2026 | 15.31% |
| Dec 31, 2025 | 19.73% |
| Sep 30, 2025 | -15.70% |
| Jun 30, 2025 | -9,430.07% |
| Mar 31, 2025 | 100.69% |
| Dec 31, 2024 | -8.67% |
| Sep 30, 2024 | -140.35% |
| Jun 30, 2024 | 275.33% |
| Mar 31, 2024 | -170.79% |
| Dec 31, 2023 | -729.93% |
| Sep 30, 2023 | 95.86% |
| Jun 30, 2023 | -131.94% |
| Mar 31, 2023 | 17.47% |
| Dec 31, 2022 | -33.06% |
| Sep 30, 2022 | -3.12% |
| Jun 30, 2022 | 12.43% |
| Mar 31, 2022 | 32.54% |
| Dec 31, 2021 | -78.00% |
| Sep 30, 2021 | -2.73% |